Mohebtash 2011.

Methods	Uncontrolled study
Participants	31 metastatic ovarian and breast cancer patients (ovarian cancer n = 14)
Interventions	Subcutaneous recombinant pox virus (MUC1 and CEA) Adjuvant: local GM‐CSF
Outcomes	Survival: median time to progression 2 months (range 1 to 36) Immune responses (cellular) Adverse events: no severe adverse events, mostly locoregional grade 1 or 2 reactions
Notes	Max 3 patients overlap with Gulley 2008
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Uncontrolled trial
Allocation concealment (selection bias)	High risk	Uncontrolled trial
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Selective reporting (reporting bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Other bias	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’